重视促排卵的质量与安全性

doi:10.7504/fk2014120102

摘要/Abstract

摘要：

促排卵治疗是决定辅助生殖成功率的关键步骤，随着促排卵药物的大量应用，促排卵治疗方式的选择及并发症带来的风险也日益受到关注。这一领域需要更多的大样本、多中心临床研究和动物试验研究，以此指导促排卵的临床合理应用。

Abstract:

Abstract: Ovulation induction is a key step to the successful pregnancy in assisted reproductive treatment.with a large number of application, drug selection, risks and complications get more attention. More large sample and multi-center clinical trials and animal experiments in this area were needed, so as to guide the rational clinical application of ovulation induction.

Key words: assisted reproductive technology, ovulation induction；oocyte quality；safety

中图分类号:

Ｒ321-33

乔杰，张曜耀，李蓉. 重视促排卵的质量与安全性[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014120102.

QIAO Jie，ZHANG Yao-yao,LI Rong.. Pay attention to the quality and safety of ovulation induction.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014120102.

参考文献

［1］   Falck B. Site of production of oestrogen in the ovary of the rat［J］. Nature, 1959, 184(Suppl 14): 1082.

［2］   Eppig JJ, Hosoe M, O'brien MJ, et al. Conditions that affect acquisition of developmental competence by mouse oocytes in vitro: FSH, insulin, glucose and ascorbic acid［J］. Mol Cell Endocrinol, 2000, 163(1-2): 109-16.

［3］    李敏, 李蓉, 乔杰. 促排卵药物对卵母细胞和子宫内膜的影响［J］. 中国实用妇科与产科杂志, 2013,29(6): 409-411.

［4］   Balasch J, Creus M, Fabregues F, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction［J］. J Assist Reprod Genet, 2001, 18(5): 250-256.

［5］   Franco JG, Baruffi RL, Oliveira JB, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study［J］. Reprod Biol Endocrinol, 2009, 7: 58.

［6］   Lisi F, Rinaldi L, Fishel S, et al. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization［J］. Fertil Steril, 2005, 83(2): 309-315.

［7］ Venetis CA, Kolibianakis EM, Tarlatzi TB, et al. Benefits of luteinizing hormone activity in ovarian stimulation for IVF［J］. Reprod Biomed Online, 2009, 18 Suppl 2: 31-36.

［8］   Kovacs P, Kovats T, Kaali SG. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization［J］. Fertil Steril, 2010, 93(2): 475-479.

［9］   Kolibianakis EM, Kalogeropoulou L, Griesinger G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis［J］. Hum Reprod Update, 2007, 13(5): 445-452.

［10］   Mochtar MH, Van Der V, Ziech M, et al. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles［J］. Cochrane Database Syst Rev, 2007, (2): CD005070.

［11］   Yazici YF, Gorkemli H, Colakoglu MC, et al. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation［J］. Gynecol Endocrinol, 2014: 1-4.

［12］   Konig TE, Van Der Houwen LE, Overbeek A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study［J］. Hum Reprod, 2013, 28(10): 2804-2812.

［13］   Hill MJ, Levens ED, Levy G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis［J］. Fertil Steril, 2012, 97(5): 1108-14 e1.

［14］   Wong PC, Qiao J, Ho C, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective［J］. Reprod Biomed Online, 2011, 23(1): 81-90.

［15］   Tain CF, Goh VH, Ng SC. Effects of hyperstimulation with gonadotrophins and age of females on oocytes and their metaphase II status in rats［J］. Mol Reprod Dev, 2000, 55(1): 104-108.

［16］   Valbuena D, Martin J, De Pablo JL, et al. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo［J］. Fertil Steril, 2001, 76(5): 962-968.

［17］   Massart P, Sermondade N, Dupont C, et al. ［Elective cryopreservation of all embryos in women at risk of ovarian hyperstimulation syndrome: prevention and efficiency［J］. Gynecol Obstet Fertil, 2013, 41(6): 365-371.

［18］   Chen QJ, Sun XX, Li L, et al. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH)［J］. Acta Obstet Gynecol Scand, 2007, 86(7): 849-854.

［19］   Ng EH, Lau EY, Yeung WS, et al. Oocyte and embryo quality in patients with excessive ovarian response during in vitro fertilization treatment［J］. J Assist Reprod Genet, 2003, 20(5): 186-191.

［20］   Young SL. Oestrogen and progesterone action on endometrium: a translational approach to understanding endometrial receptivity［J］. Reprod Biomed Online, 2013, 27(5): 497-505.

［21］   Melo MA, Meseguer M, Garrido N, et al. The significance of premature luteinization in an oocyte-donation programme［J］. Hum Reprod, 2006, 21(6): 1503-1507.

［22］   Wu Z, Li R, Ma Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles［J］. Reprod Biomed Online, 2012, 24(5): 511-520.

［23］    李蓉, 武泽, 乔杰. 超排卵周期提前黄体酮升高与提前黄素化［J］. 生殖医学杂志, 2013, (10): 792-794.

［24］    李蓉, 乔杰, 武泽. 超促排卵周期中孕酮升高对胚胎植入的影响［J］. 生殖医学杂志, 2013, 22(4): 230-235.

［25］   Wiser A, Gonen O, Ghetler Y, et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study［J］. Hum Reprod, 2010, 25(10): 2496-2500.

［26］   Xu B, Li Z, Yue J, et al. Effect of dehydroepiandrosterone administration in patients with poor ovarian response according to the Bologna criteria［J］. PLoS One, 2014, 9(6): e99858.

［27］   Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial［J］. J Assist Reprod Genet, 2008, 25(4): 123-127.

［28］   Kyrou D, Kolibianakis EM, Venetis CA, et al. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis［J］. Fertil Steril, 2009, 91(3): 749-766.

［29］   Reh A, Krey L, Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center［J］. Fertil Steril, 2010, 93(1): 101-108.

［30］    任昀, 杨硕, 杨蕊,等. 促性腺激素释放激素激动剂长方案与拮抗剂方案对体外受精治疗妊娠结局的影响［J］. 北京大学学报(医学版), 2013, 45(6): 877-881.

［31］   Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles［J］. Fertil Steril, 2014, 101(1): 105-111.

［32］    唐奕, 张红, 罗克莉, 等. 黄体期促排卵方案在卵巢低反应患者中的初步研究［J］. 生殖与避孕, 2014, 34(6): 462-466.

［33］   Celik C, Gezginc K, Aktan M, et al. Effects of ovulation induction on ovarian morphology: an animal study［J］. Int J Gynecol Cancer, 2004, 14(4): 600-606.

［34］   Karin S, Peter C, Kjell B, et al. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden［J］. Fertil Steril, 2009, 91(4): 1152-1158.

［35］   Dauplat J, Chene G, Pomel C, et al. Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer［J］. Eur Cancer (Oxford, England : 1990), 2009, 45(17): 2977-2983.

［36］   Rossing MA, Daling JR, Weiss N S, et al. Ovarian tumors in a cohort of infertile women［J］. N Engl J Med, 1994, 331(12): 771-776.

［37］   Jensen A, Sharif H, Frederiksen K, et al. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study［J］. BMJ, 2009, 338: b249.

［38］   Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs［J］. Obstet Gynecol, 2004, 103(6): 1194-1203.

［39］   Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women［J］. Am J Epidemiol, 1998, 147(11): 1038-1042.

［40］   Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women［J］. Am J Epidemiol, 1987, 125(5): 780-790.

［41］   Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation［J］. Am J Epidemiol, 2005, 161(7): 607-615.

［42］   Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization［J］. Fertil Steril, 2002, 77(2): 324-327.

［43］   Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK［J］. Hum Reprod, 2002, 17(8): 2209-2213.

［44］   Siristatidis C, Sergentanis TN, Kanavidis P, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis［J］. Hum Reprod Update, 2013, 19(2): 105-123.

［45］   Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs［J］. Hum Reprod, 2004, 19(9): 2005-2013.

［46］   Jensen A, Sharif H, Svare EI, et al. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study［J］. Cancer Epidemiol Biomarkers Prev, 2007, 16(7): 1400-1407.

［47］   Kristiansson P, Bjor O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment［J］. Hum Reprod, 2007, 22(2): 421-426.

［48］   Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment［J］. Lancet, 2005, 365(9473): 1807-1816.

[1]	黄晨阳, 孙海翔. 妇科恶性肿瘤患者促排卵及胚胎移植方案的选择[J]. 中国实用妇科与产科杂志, 2022, 38(6): 614-618.
[2]	史潇, 全松. 女性生育力保存相关伦理问题及对策[J]. 中国实用妇科与产科杂志, 2022, 38(6): 618-621.
[3]	邓姗, 田秦杰. 子宫内膜息肉与生育[J]. 中国实用妇科与产科杂志, 2022, 38(3): 273-276.
[4]	赵扬玉，乔杰. 辅助生殖技术助孕双胎妊娠临床管理建议[J]. 中国实用妇科与产科杂志, 2021, 37(7): 724-730.
[5]	周灿权. 恰当进行黄体支持，避免过度医疗[J]. 中国实用妇科与产科杂志, 2021, 37(4): 409-411.
[6]	白诗雨，张建平. 黄体支持在复发性妊娠丢失中的作用[J]. 中国实用妇科与产科杂志, 2021, 37(4): 427-431.
[7]	黄珈. 黄体期促排卵的利弊分析[J]. 中国实用妇科与产科杂志, 2021, 37(4): 435-440.
[8]	刘芬婷, 李蓉. 女性生殖道感染对辅助生殖技术妊娠结局的影响#br#[J]. 中国实用妇科与产科杂志, 2021, 37(10): 1007-1012.
[9]	邵小光，魏晗. 辅助生殖技术中薄型子宫内膜的诊断标准与临床处理[J]. 中国实用妇科与产科杂志, 2020, 36(6): 496-500.
[10]	刘婧，全松. 辅助生殖技术中围胚胎移植期宫腔积液及其处理[J]. 中国实用妇科与产科杂志, 2020, 36(6): 504-507.
[11]	许彬，李艳萍. 子宫内膜蠕动波与胚胎着床[J]. 中国实用妇科与产科杂志, 2020, 36(6): 507-512.
[12]	邓晓惠，崔妍婷. 妇科恶性肿瘤与辅助生殖技术[J]. 中国实用妇科与产科杂志, 2019, 35(6): 644-646.
[13]	张云山，杨琨. 构建严谨的辅助生殖技术伦理和法规管理体系[J]. 中国实用妇科与产科杂志, 2018, 34(6): 608-612.
[14]	张帝开，李佳琛. 阴道微生态环境对辅助生殖技术安全性影响[J]. 中国实用妇科与产科杂志, 2018, 34(6): 605-608.
[15]	刘见桥，吴乙璇. PDCA循环在辅助生殖技术中的应用——以胚胎污染为例[J]. 中国实用妇科与产科杂志, 2018, 34(6): 602-605.